4.

PFS多因素分析

Multivariate analysis of progression-free survival

Variable	Patients n (%)	Median PFS (mo)	P	HR (95%CI)
Age (yr)			0.314, 0	0.701 (0.350-1.400)
≥65	18	3.0
< 65	43	3.5
Gender			0.937, 0	0.960 (0.353-2.610)
Male	17	3.0
Female	44	3.0
Smoking status			0.276, 0	0.531 (0.170-1.657)
Never	51	3.0
Current or ever	10	2.5
ECOG			0.433, 8	0.797 (0.451-1.407)
0-1	30	4.0
≥2	31	3.0
EGFR mutation			0.148, 3	0.677 (0.324-1.211)
(+)	34	3.5
(-)	4	2.35
Number of metastasized organs			0.766, 6	0.871 (0.350-2.169)
1-2	40	4.0
≥3	21	3.0
Metastasized region
Lung	47	4.0	0.719, 0	0.719 (0.371-1.394)
Brain	30	3.0	0.052, 0	0.477 (0.266-1.007)
Liver	12	3.0	0.576, 4	0.797 (0.360-1.766)
Bone	27	3.0	0.117, 6	0.553 (0.264-1.161)
Response of initial TKI			0.977, 7	0.990 (0.482-2.034)
CR+PR	44	3.75
SD	17	2.0
PFS of initial TKI			0.046, 9	0.317 (0.102-0.984)
≥6 months	55	4.0
< 6 months	6	1.0
Interval chemotherapy			0.112, 7	0.398 (0.127-1.243)
Yes	50	4.0
No	11	1.5
Interval time			0.011, 3	0.224 (0.071-0.713)
≥3 months	50	4.0
< 3 months	11	1.0